Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.53 |
| ▸ | HTR1D | P28221 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 7/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | PCSK9 | Q8NBP7 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6577815 | 0.99 | ADRB2 (0.52) | ADRB2HTR1DHTR6HTR2APCSK9 | |
| SCHEMBL6577839 | 0.90 | HTR2A (0.57) | ADRB2HTR1DHTR6HTR2A | |
| Hydrochloric Acid SCHEMBL6580166 | 0.89 | HTR2A (0.56) | ADRB2HTR1DHTR6HTR2A | |
| SCHEMBL7163717 | 0.85 | HTR6 (0.43) | HTR6PCSK9GAATP53KMT2A | |
| Hydrochloric Acid SCHEMBL6577292 | 0.84 | HTR6 (0.43) | HTR6PCSK9GAATP53KMT2A | |
| SCHEMBL27873084 | 0.84 | ADRB2 (0.58) | ADRB2HTR1DHTR6HTR2AKMT2A | |
| SCHEMBL27867012 | 0.83 | ADRB2 (0.57) | ADRB2HTR1DHTR6HTR2AKMT2A | |
| SCHEMBL6580203 | 0.83 | GAA (0.40) | ADRB2HTR1DHTR6PCSK9GAA | |
| SCHEMBL6575474 | 0.82 | HTR6 (0.46) | ADRB2HTR1DHTR6HTR2AGAA | |
| SCHEMBL14297213 | 0.82 | HTR1D (0.66) | ADRB2HTR1DHTR6HTR2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6565829-B2 | Psychological disorders; central nervous system disorders | PHARMACIA & UPJOHN COMPANY | 2003-05-20 | — | — | US | claimed |
| US-20030060498-A1 | 5-arylsulfonyl indoles useful for treating disease | PHARMACIA & UPJOHN COMPANY | 2003-03-27 | — | — | US | claimed |
| EP-1411925-A1 | 5-ARYLSULFONYL INDOLES HAVING 5-HT6 RECEPTOR AFFINITY | PHARMACIA & UPJOHN COMPANY (US) | 2004-04-28 | — | — | EP | disclosed |
| US-6565829-B2 | Psychological disorders; central nervous system disorders | PHARMACIA & UPJOHN COMPANY | 2003-05-20 | — | — | US | disclosed |
| US-20030060498-A1 | 5-arylsulfonyl indoles useful for treating disease | PHARMACIA & UPJOHN COMPANY | 2003-03-27 | — | — | US | disclosed |
| WO-2003011284-A1 | 5-ARYLSULFONYL INDOLES HAVING 5-HT6 RECEPTOR AFFINITY | PHARMACIA & UPJOHN COMPANY (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060498-A1 | 5-arylsulfonyl indoles useful for treating disease | IDO1, HTR5A, IDO2 | ADRB2 209/4885HTR1D 33/4885HTR6 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.